PMID- 25760304
OWN - NLM
STAT- MEDLINE
DCOM- 20160111
LR  - 20150415
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 12
IP  - 1
DP  - 2015 Jul
TI  - Beneficial effects of tripterygium glycosides tablet on biomarkers in patients 
      with ankylosing spondylitis.
PG  - 684-90
LID - 10.3892/mmr.2015.3448 [doi]
AB  - The aim of the current study was to explore the effects and possible mechanisms 
      of tripterygium glycosides tablet (TGT) in the treatment of active ankylosing 
      spondylitis (AS). Thirty-six patients with active AS were given a 20 mg TGT 
      treatment three times per day for 12 weeks, and 21 unrelated healthy controls 
      were recruited as the control group. Efficacy measures included the Bath AS 
      disease activity index (BASDAI), erythrocyte sedimentation rate (ESR) and 
      C-reactive protein (CRP) prior and subsequent to TGT treatment. Serum dickkopf 
      homolog 1 (DKK1) and interleukin-17 (IL-17) levels before and after TGT treatment 
      were assessed using reverse transcription-quantitative polymerase chain reaction 
      (RT-qPCR) and ELISA assay. The levels of several serum biomarkers were determined 
      by ELISA, including receptor activator of nuclear factor kappa-B ligand (RANKL), 
      osteoprotegerin (OPG), bone alkaline phosphatase (BAP), bone morphogenetic 
      protein-2 (BMP-2), matrix metalloproteinase-3 (MMP-3), cross-linked telopeptide 
      of type II collagen (CTX-II), vascular endothelial growth factor (VEGF), and 
      prostaglandin E2 (PGE2). After 12 weeks of TGT treatment, the BASDAI score of the 
      patients was significantly reduced (P<0.05), their levels of ESR and CRP were 
      significantly reduced to a normal level (P<0.05, P<0.05), RT-PCR and ELISA showed 
      a significant increase in the level of DKK1 expression (P<0.05) and a significant 
      decreased IL-17 expression (P<0.05), there was a significant increase in the 
      expression of OPG, BAP and BMP-2 (P<0.01, P<0.01, P<0.01) and a significant 
      reduction in the expression levels of RANKL, CTX-II. MMP-3, PGE2, and VEGF 
      (P<0.01, P<0.01, P<0.01, P<0.05, P<0.01) compared with those of the controls. TGT 
      is effective at improving the signs and symptoms of patients with AS through the 
      regulation of serum biomarkers, and the mechanisms may be associated with the 
      anti-inflammatory effect, inhibition of new bone formation and potential 
      bone-protective effects.
FAU - Ji, Wei
AU  - Ji W
AD  - Department of Rheumatology, Affiliated Hospital of Nanjing University of 
      Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China.
FAU - Chen, Yajun
AU  - Chen Y
AD  - Department of Rheumatology, Affiliated Hospital of Nanjing University of 
      Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China.
FAU - Zhao, Xia
AU  - Zhao X
AD  - Department of Rheumatology, Affiliated Hospital of Nanjing University of 
      Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China.
FAU - Guo, Yunke
AU  - Guo Y
AD  - Department of Rheumatology, Affiliated Hospital of Nanjing University of 
      Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China.
FAU - Zhong, Lingyu
AU  - Zhong L
AD  - Department of Rheumatology, Affiliated Hospital of Nanjing University of 
      Traditional Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China.
FAU - Li, Honggang
AU  - Li H
AD  - Department of Rheumatology and Immunology, Zhuzhou City Hospital, Zhuzhou, Hunan 
      412000, P.R. China.
FAU - Wang, Dan
AU  - Wang D
AD  - Department of Tuberculosis, Nanjing Chest Hospital, Nanjing, Jiangsu 210029, P.R. 
      China.
FAU - Song, Yanna
AU  - Song Y
AD  - Department of Immunity, Nanjing Jiangbei People's Hospital, Nanjing, Jiangsu 
      210048, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150306
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Biomarkers)
RN  - 0 (DKK1 protein, human)
RN  - 0 (Glycosides)
RN  - 0 (IL17A protein, human)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Interleukin-17)
RN  - 0 (Tablets)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Biomarkers/*blood
MH  - C-Reactive Protein
MH  - Female
MH  - Glycosides/*administration & dosage/chemistry
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/blood
MH  - Interleukin-17/blood
MH  - Male
MH  - Spondylitis, Ankylosing/blood/*drug therapy
MH  - Tablets/administration & dosage
MH  - Tripterygium/*chemistry
EDAT- 2015/03/12 06:00
MHDA- 2016/01/12 06:00
CRDT- 2015/03/12 06:00
PHST- 2014/02/14 00:00 [received]
PHST- 2014/11/19 00:00 [accepted]
PHST- 2015/03/12 06:00 [entrez]
PHST- 2015/03/12 06:00 [pubmed]
PHST- 2016/01/12 06:00 [medline]
AID - 10.3892/mmr.2015.3448 [doi]
PST - ppublish
SO  - Mol Med Rep. 2015 Jul;12(1):684-90. doi: 10.3892/mmr.2015.3448. Epub 2015 Mar 6.